

1 **Automating the generation of antimicrobial resistance surveillance reports: a proof-**  
2 **of-concept study in seven hospitals in seven countries**

3

4 Cherry Lim<sup>1,2</sup> MSc, Thyl Miliya<sup>3</sup> MD, Vilada Chansamouth<sup>4</sup> MD, Myint Thazin Aung<sup>5</sup> PhD,  
5 Abhilasha Karkey<sup>2,6,18</sup> PhD, Prapit Teparrukkul<sup>7</sup> MD, Rahul Batra<sup>8</sup> MD, Lan Nguyen Phu  
6 Huong<sup>9</sup> PhD, John Stelling<sup>10</sup> MD MPH, Paul Turner<sup>2,3</sup> FRCPath, Elizabeth Ashley<sup>2,4,11</sup> MBBS,  
7 Rogier H van Doorn<sup>2,12</sup> MD, Htet Naing Lin<sup>11</sup> MD, Clare Ling<sup>13</sup> PhD, Soawapak Hinjoy<sup>14,15</sup>  
8 DrPH, Sopon Iamsirithaworn<sup>16</sup> PhD, Susanna J Dunachie<sup>1,2</sup> PhD, Tri Wangrangsamakul<sup>1,2</sup>  
9 MRCP FRCPath, Viriya Hantrakun<sup>1</sup> PhD, William Schilling<sup>1,2</sup> MD, Yen Lam Minh<sup>12</sup> MD, Tan  
10 Le Van<sup>12</sup> PhD, Htay Htay Hlaing<sup>5</sup> MD, Mayfong Mayxay<sup>2,4,17</sup> MD, Manivanh Vongsouvath<sup>4</sup>  
11 MD, Buddha Basnyat<sup>2,6,12,18</sup> FRCPE, Jonathan Edgeworth<sup>8</sup> FRCP, Sharon J Peacock<sup>19</sup>  
12 FRCP, Guy Thwaites<sup>2,12</sup> FRCP, Nicholas PJ Day<sup>1,2</sup> FRCP, Ben S Cooper<sup>1,2</sup> PhD, Direk  
13 Limmathurotsakul<sup>1,2</sup> PhD

14

15 <sup>1</sup>Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol  
16 University, Thailand

17 <sup>2</sup>Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University  
18 of Oxford, United Kingdom

19 <sup>3</sup>Cambodia-Oxford Medical Research Unit, Angkor Hospital for Children, Siem Reap  
20 Cambodia

21 <sup>4</sup>Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Mahosot  
22 Hospital, Vientiane, Lao People's Democratic Republic

23 <sup>5</sup>North Okkalapa General and Teaching Hospital, Yangon, Myanmar

24 <sup>6</sup>Patan Hospital, Kathmandu, Nepal

25 <sup>7</sup>Sunpasitthiprasong Hospital, Ubon Ratchathani, Thailand

26 <sup>8</sup>Centre for Clinical Infection and Diagnostic Research (CIDR), Department of Infectious  
27 Diseases, King's College London & Guy's and St. Thomas' NHS Foundation Trust, United  
28 Kingdom

29 <sup>9</sup>The Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam

30 <sup>10</sup>Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

31 <sup>11</sup>Myanmar Oxford Clinical Research Unit, Yangon, Myanmar

32 <sup>12</sup>Oxford University Clinical Research Unit, Hanoi and Ho Chi Minh City, Vietnam

33 <sup>13</sup>Shoklo Malaria Research Unit, Mahidol Oxford Tropical Medicine Research Unit, Faculty of  
34 Tropical Medicine, Mahidol University, Mae Sot, Thailand

35 <sup>14</sup>Bureau of Epidemiology, Department of Disease Control, Ministry of Public Health,  
36 Nonthaburi, Thailand

37 <sup>15</sup>Office of International Cooperation, Department of Disease Control, Ministry of Public  
38 Health, Nonthaburi, Thailand.

39 <sup>16</sup>Division of Communicable Diseases, Department of Disease Control, Ministry of Public  
40 Health, Nonthaburi, Thailand

41 <sup>17</sup>Institute of Research and Education Development (IRED), University of Health Sciences,  
42 Vientiane, Lao People's Democratic Republic

43 <sup>18</sup>Oxford University Clinical Research Unit, Patan Hospital, Kathmandu, Nepal

44 <sup>19</sup>Department of Medicine, University of Cambridge, United Kingdom

45

46 **Corresponding author:** Cherry Lim. Mahidol Oxford Tropical Medicine Research Unit,  
47 Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Road, Bangkok, 10400,  
48 Thailand. Tel: +66 2 354 6333, Fax: +66 2 354 9169, Email: [cherry@tropmedres.ac](mailto:cherry@tropmedres.ac)

49

50 **Alternative Corresponding author:** Direk Limmathurotsakul. Mahidol Oxford Tropical  
51 Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi  
52 Road, Bangkok, 10400, Thailand. Tel: +66 2 354 6333, Fax: +66 2 354 9169, Email:  
53 [direk@tropmedres.ac](mailto:direk@tropmedres.ac)

54

55 **Keywords:** antimicrobial-resistance, surveillance, report, data analysis, application

56

57 **ABSTRACT**

58

59 **Background**

60 Reporting cumulative antimicrobial susceptibility testing data on a regular basis is crucial to  
61 inform antimicrobial resistance (AMR) action plans at local, national and global levels.  
62 However, analysing data and generating a report are time-consuming and often require  
63 trained personnel. We illustrate the development and utility of an offline, open-access and  
64 automated tool that can support the generation of AMR surveillance reports promptly at the  
65 local level.

66

67 **Methods**

68 An offline application to generate standardized AMR surveillance reports from routinely  
69 available microbiology and hospital data files was written in the R programming language.  
70 The application can be run by a double-click on the application file without any further user  
71 input. The data analysis procedure and report content were developed based on the  
72 recommendations of the World Health Organization Global Antimicrobial Resistance  
73 Surveillance System (WHO GLASS). The application was tested in Microsoft Windows 10  
74 and 7 using open-access example data sets. We then independently tested the application  
75 in seven hospitals in Cambodia, Lao People's Democratic Republic (PDR), Myanmar, Nepal,  
76 Thailand, the United Kingdom, and Vietnam.

77

78 **Findings**

79 We developed the AutoMated tool for Antimicrobial resistance Surveillance System  
80 (AMASS), which can support clinical microbiology laboratories to analyse their microbiology  
81 and hospital data files (in CSV or Excel format) onsite and promptly generate AMR  
82 surveillance reports (in PDF and Excel formats). The data files could be those exported from  
83 WHONET and/or other laboratory information systems. The automatically generated reports  
84 contain only summary data without patient identifiers. The AMASS application is  
85 downloadable from [www.amass.website](http://www.amass.website). The participating hospitals tested the application  
86 and deposited their AMR surveillance reports in an open-access data repository.

87

88 **Interpretation**

89 The AMASS application can be a useful tool to support the generation and sharing of AMR  
90 surveillance reports.

91

92 **Funding**

93 Mahidol Oxford Tropical Medicine Research Unit (MORU) is funded by the Wellcome Trust  
94 (Grant no. 106698/Z/14/Z). Oxford University Clinical Research Unit (OUCRU) is funded by  
95 the Wellcome Trust (Grant no. 106680/B/14/Z). The investigators are funded by the  
96 Wellcome Trust (CL is funded by a Training Research Fellowship [Grant no. 206736] and DL  
97 is funded by an Intermediate Training Fellowship [Grant no. 101103]). BSC is funded by the  
98 UK Medical Research Council and Department for International Development (Grant no.  
99 MR/K006924/1). The funder has no role in the design and conduct of the study, data  
100 collection, or analysis and interpretation of the data.

101

102

## 103 INTRODUCTION

104 Generating and sharing antimicrobial resistance (AMR) surveillance reports are fundamental  
105 elements of actions against AMR infections at local, national and international levels.  
106 Information on patterns of antimicrobial susceptibility is important to guide empiric choice of  
107 therapy, monitor resistance trends and detect outbreaks of AMR infections at the local level  
108 [1-3]. Combining data and reports at the national level provides evidence to inform the  
109 implementation of national action plans, decide on resource allocation for interventions, and  
110 monitor the impact of those interventions [3-5]. The Review on AMR chaired by Jim O'Neill  
111 estimated that 700,000 global deaths are attributable to AMR infections each year (including  
112 bacterial infections, HIV, TB and malaria) [6], and had an enormous global impact [7,8].  
113 While this represents a very rough estimate subject to well-documented limitations [1,9,10],  
114 importantly the report highlighted the need for improved AMR surveillance.

115  
116 Methods to analyse data and generate AMR surveillance reports are gradually being  
117 standardised worldwide [3,11-15]. Recently, the World Health Organization (WHO) launched  
118 the Global Antimicrobial Resistance Surveillance System (GLASS) attempting to standardize  
119 the AMR surveillance data reporting format [11,16,17]. In general, it is recommended that (a)  
120 duplicated results on bacterial isolates should be removed, and (b) data should be stratified  
121 by origin of infection (community or hospital) whenever possible [11,15]. A simple de-  
122 duplication process is to include only the first isolate of a species per patient per specimen  
123 type per survey period in the report [3,11]. The origin of infection is defined by using  
124 specimen collection date and hospital admission date as a proxy to define where the  
125 infection was likely contracted (community or hospital) [3,11].

126  
127 Even in areas where AMR surveillance data are available, there are many barriers to  
128 utilizing such data [18]. Many hospitals in low and middle-income countries (LMICs) lack the  
129 time and resources needed to analyse the data (particularly to de-duplicate and validate the  
130 accuracy of the summary data), write the reports, and to release the data or reports [18].  
131 There are open-access Laboratory Information Systems (LIS) [19], and microbiology  
132 laboratory database softwares, including WHONET [20], that are useful for recording and  
133 analysing the data, and generating figures to support the generation of AMR surveillance  
134 reports for hospitals in LMICs. There are no freely-available automated system that can  
135 generate summary reports for immediate use and be operated by non-technical staff. In  
136 addition, to generate AMR surveillance reports stratified by the origin of infection, additional  
137 data on hospital admission are frequently needed [21-24]. This is because hospital  
138 admission dates are not generally collected in microbiology laboratory data. In many hospital  
139 settings microbiology and hospital admission data are held in separate computers or

140 systems with restricted access. Even in high-income countries, many hospitals lack well-  
141 trained clinical microbiologists, epidemiologists or data experts with adequate skills in  
142 statistical software (such as R, SAS, SPSS and STATA) to merge and de-duplicate data in  
143 the separated databases and generate reports stratified by the origin of infection.

144

145 Here, we developed an application, termed AutoMated tool for Antimicrobial resistance  
146 Surveillance System (AMASS), which can support a local hospital to independently analyse  
147 routinely collected electronic data and rapidly generate AMR surveillance reports. We tested  
148 AMASS in seven hospitals in Cambodia, Lao PDR, Myanmar, Nepal, Thailand, the United  
149 Kingdom and Vietnam, and deposited the report from each hospital in an open-access  
150 platform.

151

152

## 153 **METHODS**

### 154 **Design of the application**

155 The tool operates by reading and processing the raw data files to automatically produce  
156 AMR surveillance reports. To ensure the tool is fully open access, we built the application in  
157 R (version 3.6.2), which is a free software environment. We then placed the application  
158 within a user-friendly interface, which only requires a double-click on the application file to  
159 run the automation without the need to understand the R program. We included both the R  
160 portable (version 3.4.3) and RStudio (version 1.1.423) within the downloadable package so  
161 that the application can run without the need to install R or any program prior to running the  
162 application.

163

### 164 **Data processing and statistical analysis**

165 A schematic overview of input data, data processing, statistical analyses and output is  
166 shown in Supplementary Figure 1. In brief, input data are microbiology data files (in CSV or  
167 Excel formats) with or without hospital data files, which can be exported from WHONET or a  
168 LIS with data export capacity. The data processing and analysis algorithms, including data-  
169 deduplication, were developed based on the WHO GLASS recommendations [11,17]. The  
170 reports were designed to have a similar format to the WHO GLASS 2018 report [14].

171

172 The application de-duplicates the data by including only the first isolate per sample type per  
173 pathogen per survey period for each patient [11]. The application currently includes only  
174 blood specimens, and eight pathogens: namely *Acinetobacter* spp., *Escherichia coli*,  
175 *Enterococcus* spp., *Klebsiella pneumoniae*, *Salmonella* spp., *Staphylococcus aureus*,  
176 *Streptococcus pneumoniae*, and *Pseudomonas aeruginosa*. Both *Enterococcus* spp., and *P.*

177 *aeruginosa* were added on top of the six priority pathogens described by the WHO GLASS  
178 for bacteraemia [17,25] because both pathogens are common causes of bacteraemia  
179 [15,21], and were included in the 2015 global priority list of AMR bacteria [25]. The list of  
180 pathogen-antibiotic combinations was modified from the WHO GLASS (Supplementary  
181 Table 1). Infections are stratified into community-origin or hospital-origin using hospital  
182 admission dates and specimen collection dates, when available [11,17]. Patients with the  
183 first specimen culture positive for the pathogen taken in the outpatient setting or on the first  
184 or second day of hospitalization are classified as having community-origin infection [11,17].  
185 Patients with the first specimen culture positive for the pathogen taken on hospital day three  
186 or later are classified as having hospital-origin infection [11,17]. Alternatively, in cases where  
187 users have data on origin of infection assigned by the attending physicians or infection  
188 control team of the hospital, AMASS can instead use those categorizations to stratify the  
189 infection into community-origin or hospital-origin. Prevalence and incidence rates are  
190 estimated based on the recommendations of the WHO GLASS (Supplementary Text 1)  
191 [11,17]. An additional report on mortality involving AMR and non-AMR infections is  
192 generated when mortality data are available in the hospital admission data file. The term  
193 “mortality involving AMR and antimicrobial-susceptible infections” is used because the  
194 mortality reported in the hospital admission data are all-cause mortality [1]. This measure of  
195 mortality includes deaths caused or contributed by other underlying and intermediate causes.  
196 Therefore, the term “involving AMR infections” is used, in accordance with the term used by  
197 the UK Office for National Statistics [26,27].

198

### 199 **Example data sets**

200 Two example data sets are provided in the downloadable package of the AMASS application.  
201 The first example data set is the open-access demonstration file from WHONET [19]. The  
202 second example data set is a hypothetical data set generated for AMASS. The second  
203 example data set was created to represent a large data set from a 1000-bed hospital,  
204 containing both microbiology and hospital admission data. A detailed description on how the  
205 second example data set was hypothetically generated is in Supplementary Text 2. In brief,  
206 two synthetic data files (*microbiology\_data.xls* and *hospital\_admission\_data.xls* files) were  
207 generated based on the summary data in the AMR surveillance report from 2015 of  
208 Sunpasitthiprasong Hospital, Ubon Ratchathani, Thailand. Variables in the microbiology data  
209 file include hospital number (HN), specimen type, specimen collection date, culture result,  
210 and antibiotic susceptibility testing result, and each row contains information for each  
211 specimen. Variables in the hospital admission data file include HN, age, sex, admission date,  
212 discharge date and in-hospital discharge outcome. All data were randomly generated using  
213 STATA 15.1 (Texas, USA).

214

## 215 **Testing AMASS using hospital data**

216 Seven hospitals participated in the study: Angkor Hospital for Children in Cambodia,  
217 Mahosot Hospital in Lao PDR, North Okkalapa General and Teaching Hospital in Myanmar,  
218 Patan Hospital in Nepal, Sunpasitthiprasong Hospital in Thailand, St Thomas' Hospital in the  
219 United Kingdom, and the Hospital for Tropical Diseases in Vietnam. The hospitals were  
220 selected because microbiology data are collected routinely, and they have prior experience  
221 in data quality controls. Moreover, the hospitals varied in LIS used for data storage and are  
222 good examples to demonstrate the practicality and usability of AMASS in different settings,  
223 to a wider audience. The study was approved by the Oxford Tropical Research Ethics  
224 Committee, University of Oxford, and local Ethics Committees. C.L. corresponded with the  
225 participating hospitals and demonstrated how the application operates using the example  
226 data files. The local hospital staff operated the application using their local data by  
227 themselves. All microbiology and hospital data were stored independently within their  
228 hospital computers under their local data protection standards. Automatically generated  
229 reports and anonymous summary data from each hospital are publicly available and  
230 deposited in data repositories with permission from each hospital.

231

232

## 233 **RESULTS**

234

### 235 **Overview of AMASS**

236 The AMASS application has been developed to support clinical microbiology laboratories to  
237 automatically analyse hospital local data files (in CSV or Excel formats) and generate AMR  
238 surveillance reports (in PDF and Excel formats) promptly. Six steps are followed to generate  
239 the AMR surveillance reports (Figure 1 and Supplementary video file 1). (1) Download the  
240 AMASS package from [www.amass.website](http://www.amass.website). (2) Obtain routinely collected raw microbiology  
241 data file and, if available, hospital admission data file, and then, save the data files in the  
242 folder of the AMASS application. (3) Configure data dictionaries. Two data dictionaries are  
243 provided to accommodate different ways of naming variables (e.g. sex or gender) and data  
244 values (e.g. M and F, or Male and Female). How the data dictionaries functioned is  
245 described in more detail in the "Input requirements" section. (4) Double-click on the  
246 AMASS.bat file to run the application. (5) Review and validate the AMR surveillance reports  
247 (generated in PDF format) and the anonymous summary data (generated in CSV format). (6)  
248 Share the reports within the hospital, especially with the local infection control team. The  
249 reports and anonymous summary data contain no patient identifiers. Therefore, users may

250 share the reports and anonymous summary data with national and international  
251 organizations or make the reports and anonymous summary data open access.

252

### 253 **Features of AMASS**

254 Key features of the AMASS are listed in Table 1. In brief, the AMASS 1) can be downloaded  
255 from [www.amass.website](http://www.amass.website) and be used under Creative Commons Attribution 4.0  
256 International license (i.e. it is open-access); 2) only requires users to double-click on the  
257 application icon to perform data processing and analysis (i.e. user-friendly); 3) reads CSV  
258 and EXCEL files that can be exported from WHONET, LIS, or electronic health record (eHR)  
259 systems (i.e. highly compatible); and 4) can run on stand-alone and offline computers in the  
260 hospitals under their local data protection standards. All data processing and report  
261 generation are done locally, no raw data are shared, and final reports and output summary  
262 data files contain no patient identifier (i.e. high data security).

263

264 Moreover, AMASS supports the rapid use of AMR surveillance data at the local level. The  
265 readily printable report in PDF format can be reviewed and validated by non-statisticians.  
266 When errors are found in the raw data files (e.g. incomplete data) or the data dictionary files  
267 (e.g. typos), the application can be promptly re-run after fixing the errors. The summary  
268 statistics shown in the PDF report are also saved in the aggregate summary data file (in  
269 common-separated value format) ready for re-use.

270

### 271 **Input requirements**

272 To align with formats of commonly exported microbiology data and hospital admission data,  
273 AMASS reads data files in both CSV and Excel formats. The microbiology data needs to be  
274 in wide format, meaning that each row contains data from a single clinical sample. The key  
275 variables required for the microbiology data file include patient identifier, specimen collection  
276 date, specimen type, culture result, and antimicrobial susceptibility test interpretation per  
277 each antibiotic. The hospital admission data file is optional but, if available, also needs to be  
278 in wide format. The key variables needed for the hospital admission data file include patient  
279 identifier, admission date, gender, age, and, if possible, in-hospital discharge outcome. The  
280 current version of AMASS uses Gregorian calendar and required the date to be in the order  
281 of date, month, and year in any format (i.e. either text [English] or numeric).

282

283 There are two data dictionary files provided for the users to accommodate different ways of  
284 naming data variables and data values (Figure 2). The first data dictionary file  
285 (dictionary\_for\_microbiology\_data.xls) is for the microbiology data file. For example, the  
286 AMASS uses the variable name “hospital\_number” as a patient identifier (Row 3, Column A

287 of the data dictionary file). In cases where a raw microbiology data file uses a different name  
288 for the patient identifier (e.g. hn), users would need to fill “hn” in the data dictionary file (Row  
289 3, Column B of the data dictionary file). This allows the AMASS application to know that the  
290 variable “hn” of the raw microbiology data file is the patient identifier (i.e. “hospital\_number”).  
291 The second data dictionary file (dictionary\_for\_hospital\_admission\_data.xls) is for the  
292 hospital admission data file, which is to be used likewise. Supplementary video 2 is a step-  
293 by-step tutorial on how to use and configure the data dictionaries.

294

### 295 **Outputs generated by AMASS**

296 We illustrate the AMR surveillance reports generated from AMASS using the two open-  
297 access example data sets provided within the download package. Supplementary file 3 and  
298 4 contain AMR surveillance reports generated from the first and second example data sets,  
299 respectively. Supplementary video 1 illustrates how to test the AMASS using example data  
300 sets step-by-step.

301

302 In short, the automatically generated report on AMR surveillance contains six sections  
303 (Figure 3); including: [section one] data overview; [section two] an isolate-based report;  
304 [section three] an isolate-based report with stratification by origin of infection; [section four] a  
305 sample-based report; [section five] a sample-based report without stratification by infection;  
306 and [section six] mortality involving AMR and antimicrobial-susceptible infections.

307

308 AMASS uses a tier-based approach. In cases when only the microbiology data file with the  
309 results of culture positive samples is available, only section one and two are automatically  
310 generated for users (as shown by the supplementary file 3, generated from the first example  
311 data set). Section three is generated only when data on admission dates are available. This  
312 is because these data are required for the stratification by origin of infection. Section four is  
313 generated only when data of culture negative specimens (no microbial growth) are available  
314 in the microbiology data file. This is because these data are required for the sample-based  
315 approach. Section five is the section four stratified by origin of infection, and is generated if  
316 admission date data are also available. Section six would be generated only when mortality  
317 data are available (as shown by the supplementary file 4, generated from the second  
318 example data set).

319

320 AMASS also generates two log files. The first log file (generated in PDF format) is for the  
321 users to validate the input data used by AMASS to generate the AMR surveillance report. It  
322 contains information such as the total number of records analysed, age distribution, number  
323 of missing values and total number of isolates per organism in the raw microbiology data file.

324 The second log file (generated in plain text format) could be used for consultation with R  
325 users, statisticians, or the AMASS development team in case that any technical issue  
326 occurs when running AMASS.

327

### 328 **Testing AMASS in seven hospitals**

329 AMASS was tested in seven hospital in seven countries (Figure 4). The hospitals varied in  
330 data availabilities, data structure, naming of the variables, and definitions for data values  
331 (Supplementary Table 2). Overall, proportions of patients having *Escherichia coli*  
332 bacteraemia caused by 3<sup>rd</sup> generation cephalosporin resistant isolates (3GCREC) ranged  
333 from 19%-85%. The incidence rates of 3GCREC bacteraemia ranged from 283 to 2737 per  
334 100,000 tested patients among participating hospitals with available data on negative culture.

335

336 All participating hospitals deposited their output files and their data dictionary files at figshare  
337 [28-34]. Angkor Hospital for Children, North Okkalapa General and Teaching Hospital, and  
338 Sunpasithprasong Hospital had all six sections of the AMR surveillance reports, as  
339 microbiology and hospital admission data, data on negative cultures, and in-hospital  
340 discharge outcome data were available. Mahosot Hospital and Patan Hospital had section  
341 one and two in the AMR surveillance report, as only microbiology data on positive cultures  
342 was available to test in AMASS. St Thomas' Hospital had section one, two, three, and six in  
343 the AMR surveillance report because negative culture data were not available to test in  
344 AMASS. Hospital for Tropical Diseases had section one, two and four available, as hospital  
345 admission data was not available to test in AMASS.

346

347 Data storage systems varied across the hospitals. Angkor Hospital for Children used  
348 ACORN LIS which was based on Microsoft Access program [35]. Mahosot Hospital used a  
349 local LIS which was also based on Microsoft Access program [36]. Sunpasithprasong  
350 Hospital used MLAB programme [37]. St Thomas' used ICNET®  
351 (<https://www.icnetsoftware.com>), which is a commercial clinical surveillance software  
352 package. North Okkalapa General and Teaching Hospital used WHONET 2019 (modernized  
353 version of WHONET 5.6) [19]. Patan Hospital and Hospital for Tropical Diseases used an in-  
354 house LIS which was based on MySQL system. Inputting data dictionary files for the first  
355 time took about 1 to 3 hours. However, the data dictionary files could be stored and re-used  
356 when the raw microbiology data file or hospital admission data file was revised or updated.  
357 North Okkalapa General and Teaching Hospital used the data dictionary file from the  
358 example data set (in Example\_Dataset\_1\_WHONET folder), which was generated to comply  
359 with WHONET exported data (in .XLSX format; Supplementary Figure 2 illustrated how

360 microbiology data was exported from WHONET 5.6). This saved time and efforts needed to  
361 complete the data dictionaries for the hospital.

362

363 We found that the AMASS took about 1 to 3 minutes to run and automatically generate an  
364 AMR surveillance report using the local data and local hospital computers. AMASS works in  
365 Microsoft Windows 10, and with data containing a non-English (Latin and non-Latin  
366 characters) language. For example, “blood\_specimen” was recorded as “Cấy máu định danh  
367 bằng máy tự động” in the raw microbiology excel file at Hospital for Tropical Diseases,  
368 Vietnam. Another example is “Male” was recorded as “ชาย” and “Female” as recorded as  
369 “หญิง” in the raw hospital admission excel file at Sunpasitthiprasong Hospital, Thailand. By  
370 completing data dictionary files, users could use AMASS to analyse the data and generate  
371 the AMR surveillance report even though the raw data were recorded in a local language.

372

373 All participating hospitals had previous experience in data verification and in AMR  
374 surveillance report validation. All participating hospitals were familiar with the  
375 recommendations of Clinical and Laboratory Standard Institute (CLSI) and European  
376 Committee on Antimicrobial Susceptibility Testing (EUCAST) on AST data verification.  
377 Additionally, all participating hospitals were familiar with validating summary data by  
378 comparing the summary data automatically generated by the AMASS application with  
379 manual calculations.

380

381

## 382 **DISCUSSION**

383

384 We developed an open-access, offline and easy-to-use application, AMASS, which allows  
385 hospitals, especially in LMICs, to automatically generate AMR surveillance reports from  
386 routinely collected electronic microbiology data. Seven hospitals used AMASS, and shared  
387 their reports and summary data files by depositing them in an open-access data repository  
388 website. We propose that routine generation and sharing of AMR surveillance reports (i.e.  
389 cumulative antimicrobial susceptibility reports or antibiograms) in open-access data  
390 repositories from hospitals with a microbiology laboratory should be supported worldwide  
391 [38].

392

393 AMASS empowers data sharing by reducing the time and effort needed to prepare the  
394 summary data and reports without increasing the risks of breaching individual patient data  
395 confidentiality. This is because AMASS can analyse the data and generate the reports

396 promptly without needing to transfer raw data files to any party outside of their hospital. The  
397 auto-generated AMR surveillance reports are in PDF format which can be reviewed and  
398 shared locally and immediately. This is important to improve understanding of the local AMR  
399 burden and to inform local patient management. The PDF report and summary Excel files  
400 contain no individual patient-level information and can be shared with national and  
401 international organizations to support action plans on AMR. Any attempt to compare AMR  
402 surveillance reports among different hospitals should be done cautiously, as factors  
403 including the type of hospital, blood culture utilization rates and practices, and patient  
404 characteristics may influence the estimated prevalence and incidence rates of AMR  
405 infections [12-14]. An AMR surveillance report should clearly present denominators used to  
406 calculate incidence rates. Selecting an appropriate denominator that represents the local  
407 setting is important for estimating incidence rate of AMR, but remains challenging [39].  
408 AMASS calculates the total number of tested populations and used as the denominators in  
409 Section four and Section Five of the output report based on the WHO GLASS  
410 recommendation, and this denominator will not be available without data on negative culture.

411

412 AMASS uses currently recommended analytical approaches to generate the summary data  
413 and reports. All of the code is open-access, verifiable and modifiable. AMASS can also be  
414 expanded and tailored based on the local requirements. For instance, notifiable bacterial  
415 infections that are important for a local setting can be included by revising the R code  
416 provided in the AMASS package. Analytical methods can also be constantly updated and  
417 improved over time.

418

419 AMASS is an add-on automatized report generating that can be easily used, even by  
420 hospital users with limited information technology skills. It does not replace WHONET, LIS,  
421 quality assurance programmes, or antimicrobial surveillance systems (including the WHO  
422 GLASS). AMASS therefore differs from 'Macros and Excel Reports' functions of the  
423 WHONET, which allow users to regularly generate reports on screen and export data as  
424 Excel files using macro language (i.e. a series of written study parameters generated  
425 automatically through the WHONET user interface grouped together) [19]. In contrast  
426 AMASS is designed to automatically compile summary results of multiple organisms into a  
427 single report. The current version of AMASS does not support quality improvement or alert  
428 individuals to unexpected antibiogram results, which WHONET is capable of [19]. Thus,  
429 while WHONET is an appropriate choice for the main software package for microbiology  
430 laboratories in LMICs to capture and store microbiology data, and to export data for the  
431 WHO GLASS [19], AMASS provides significant additional functionality [19].

432

433 Verifying individual AST results and validating summary data in the reports (including those  
434 generated by AMASS) remain major barriers to the generation of accurate surveillance data  
435 on AMR. Only verified AST results on each patient's isolate should be used in the data  
436 analysis [12-14]. WHONET and many LIS include functions that automatically check the  
437 results to ensure that they appear reasonable or alert the users to confirm unusual results  
438 (e.g. amikacin resistance coexisting with gentamicin and tobramycin susceptibility in *E. coli*  
439 is unusual and data on such cases should be verified) [12-14,19]. In addition, it is important  
440 to validate the calculations of any analytical software used to generate the summary data  
441 and reports. We recommended users of AMASS perform manual validation (such as printing  
442 a line listing of all isolates of the species to cross-check with the reports), particularly when  
443 the program is used for the first time [12-14]. Users should also understand that the  
444 precision of the estimate is based on the sample size, which is illustrated by estimated  
445 confidence intervals. In addition, representativeness of the summary cAST data could be  
446 impacted by the sampling strategy used, particularly if blood culture is mainly collected from  
447 patients with treatment failure or prolonged hospitalizations [11,12,14]. Nonetheless,  
448 generating AMR surveillance reports from existing microbiology database could be a first  
449 step for hospitals in LMICs to understand and validate their own data, and support quality  
450 control programmes at their local level.

451

452 Local hospitals must not be discredited because of the statistics in any AMR surveillance  
453 report, as possible criticism could be a barrier to data sharing [40]. Negative criticism on the  
454 data shared by the local hospitals needs to be avoided. It is inevitable for errors to occur in  
455 any data set especially in settings with limited resources and experience on quality  
456 assurance and data validation. Tools for data validation should be provided for local  
457 hospitals, and the statistics in an AMR report should act as a guidance on the direction of  
458 improving data quality control, data validation, and infection prevention and control. Credits  
459 should be given to the hospitals that share their local AMR data and reports at an open-  
460 access data repository platform. The data repository platform, such as figshare, allows  
461 flexibility on updating the data and revising the AMR surveillance reports with appropriate  
462 version controls by the local hospitals. Publishing open-access AMR data on these platforms  
463 provides a digital object identifier (DOI) that should be used for data citation [41].

464

#### 465 **Potential issues and limitations**

466 AMASS has a number of limitations. Firstly, AMASS is not applicable for hospitals that only  
467 store data on paper forms. Secondly, AMASS cannot work with raw microbiology data file  
468 that are not in wide format or combine many files in multiple formats; for example, the raw  
469 microbiology data file where each row contains data of each antibiotic susceptibility result for

470 one single specimen. Thirdly, the current version of AMASS can only analyse microbiology  
471 data that includes antimicrobial susceptibility test interpretive categories (susceptible,  
472 intermediate, resistant) based on guidelines that the local hospital uses. Fourthly, AMASS  
473 cannot automatically validate the reliability of data that are imported into the application and  
474 used for analysis. Data verification and quality checks will be included in the future versions  
475 of the application. Fifthly, AMASS was tested with only few data sets that included non-  
476 English languages, and further testing on data with other languages may be needed. The  
477 current version of AMASS has been tested in Windows 10 and 7 and may not work under  
478 different operating systems. Finally, the current version of AMASS cannot provide options to  
479 export the AMR surveillance report in different formats (i.e. in document or text formats).  
480 However, users can re-use the summary statistics, which are saved in CSV format under the  
481 ResultData folder.

482

483

## 484 **CONCLUSION**

485

486 AMASS can be used to support hospitals with microbiology laboratories in analysing  
487 routinely collected data and generating reports with minimal resource and expertise required.  
488 This may empower individual hospitals to contribute to the understanding and actions on  
489 AMR at local settings, and maximize the utility of the local data.

490

## 491 **Acknowledgements.**

492 We thank all of the hospitals participated in the AMASS project. We thank Dr. Thet Wai Nwe  
493 from the Central Epidemiology unit of Myanmar; and Dr. Htay Htay Tin from the National  
494 Health Laboratory of Myanmar for their comments on AMASS. We also thank Dr. Kyi Soe,  
495 who is the Senior Medical Superintendent of North Okkalapa General and Teaching Hospital  
496 for his support for the AMASS and hosting the AMASS training workshop at the hospital. We  
497 thank Professor Frank Smithuis and Dr Aung Pyae Phy from MOCRU for their supports on  
498 the AMASS project. We thank Professor Paul Newton and Professor David Dance from the  
499 LOMWRU for their supports on the AMASS project. We thank Ronas Shakya from Patan  
500 Hospital, Nepal for technical assistance. We thank Joe Hessel from Diagnostic Microbiology  
501 Development Program for comments on AMASS. We thank Chotipong Chaisiripreeyakul,  
502 Techat Totemchokchaikarn, Sitthinun Pasirichusaree, and Papitchaya Achavakulthep for the  
503 tutorial videos for AMASS.

504

## 505 **Role of funding source**

506 The funders of the investigators and study had no role in the study, data collection, data  
507 analysis, data interpretation, or writing of the manuscript. The corresponding authors had the  
508 final responsibility for the decision to submit for publication.

509

#### 510 **Declaration of interests**

511 The authors declare no competing interests.


512

#### 513 **Author contributions**

514 C.Lim and D.L. conceptualized, designed, and developed AMASS, and wrote the original  
515 draft. T.M., V.C., M.T.A., A.K., P.Te., R.B., and L.N.P.H tested AMASS, curated data, and  
516 reviewed reports generated from AMASS using local data. J.S., P.Tu., E.A., R.v.D., H.N.L,  
517 C.Ling, S.H., S.I., S.D., T.W., V.H., W.S., Y.L.M., T.L.V., H.H.H., M.M., M.V., B.B., J.E.,  
518 S.J.P., G.T., N.P.J.D., and B.S.C. reviewed and interpreted the reports. All authors  
519 participated in the drafting, editing and revising the final draft.

520 **FIGURE LEGENDS**

521 **Figure 1.** A conceptual flow of AutoMated tool for Antimicrobial resistance Surveillance  
522 System (AMASS).



523


524

525 **Footnote of Figure 1.** Step 1 (Download AMASS) and step 3 (Configure data dictionary  
526 files) are one-time steps. Step 2 (obtain data), step 4 (run AMASS), step 5 (review report),  
527 and step 6 (share report) are ongoing steps that users could repeat regularly (i.e. monthly,  
528 quarterly). \*Two data dictionary files (in Excel format) are provided to allow the application to  
529 understand how variables and values of each variable are named in the raw data files in  
530 different settings. Those data dictionary files can be re-used in the subsequent runs of  
531 AMASS, as long as how variables and values of each variable are named in the raw data  
532 files remains the same. Details on how to configure the data dictionary can be found in  
533 Figure 2 and Supplementary video 2. \*\*The AMR surveillance report and summary data  
534 generated contain no patient identifiable information. The decision to share the report and  
535 summary data to national or international AMR organizations is solely up to the jurisdiction of  
536 the hospital.

537

538

539 **Figure 2.** An example of how to complete a data dictionary file



540

541

542 **Footnote of Figure 2.** For a first-time user, the user may need to complete a data dictionary

543 file, by filling in variables names used in their raw data files into the data dictionary files (e.g.

544 arrow A). This is to allow AMASS to understand that the variable "hospital\_number" used by

545 AMASS is named as "hn" in the user's raw microbiology data file. Then, users need to enter

546 how data values are named in their raw data files (e.g. arrow B). This is to allow AMASS to

547 understand that the data value named "blood\_specimen" is named as "blood" in user's raw

548 microbiology data file. Please note that the contents in the first column of the data dictionary

549 file must remain unchanged. Users can add new rows but the content in the cell in the first

550 column must not be changed. For example, users can define that both "*E. coli* (ESBLs


551 producing strain)" and "*Escherichia coli*" in their raw microbiology data file means

552 "organism\_escherichia\_coli" by AMASS. The example data dictionary files shown in the

553 figure are available in the Example\_Dataset\_2 folder (within the AMASS download package).

554


555 **Figure 3.** Examples of figures automatically generated by AMASS.



556

557 **Footnote of Figure 3.** All figures are from the report (Supplementary file 4) automatically  
 558 generated by the AMASS application using an example data set provided in the download  
 559 package. Figure 3A represents the overall proportion of non-susceptible (intermediate and  
 560 resistant) isolates in an isolate-based report (section two in the report). Figure 3B represents  
 561 proportion of non-susceptible isolates stratified by origin of infection (section three in the  
 562 report). Figure 3C represents the frequency of bloodstream infections per 100,000 tested  
 563 patients (section four in the report). Figure 3D represents mortality involving antimicrobial-  
 564 resistant and antimicrobial-susceptible bloodstream infections (section six in the report).

565 **Figure 4.** A map of participating hospitals and examples of summary data from the  
566 automatically generated AMR surveillance reports.



567 **Footnote of Figure 4.** The reports and summary data from St Thomas' Hospital, Patan  
568 Hospital, North Okkalapa General and Teaching Hospital, Mahosot Hospital,  
569 Sunpasitthiprasong Hospital, Hospital for Tropical Diseases, and Angkor Hospital for  
570 Children are open-access [28-34].  
571

572

573

574

575 **Table 1.** Features of the AMASS application

<b>Features</b>	<b>Descriptions</b>
<b>Open-access</b>	<b>AMASS is open-access and can be downloaded</b> from <a href="http://www.amass.website">www.amass.website</a> or <a href="https://figshare.com/articles/AMASS_zip/7763330">https://figshare.com/articles/AMASS_zip/7763330</a> (zip file size 177.54MB)
	<b>AMASS was developed by R, which is a free software.</b> In the download package for AMASS (AMASS.zip), there is a folder that contains R-Portable and RStudio, which supports the data processing and analysis to generate AMR surveillance report automatically.
	<b>AMASS is under CC-BY 4.0 license.</b> Users can share (copy and redistribute the material in any medium or format) and modify the R codes of the AMASS under the terms & conditions of the Creative Commons license.
<b>User-friendly</b>	<b>AMASS can be run by a double-click on the application icon.</b> Data analysis and AMR surveillance report generation are automated by the AMASS application.
	<b>Data cleaning, de-duplication, and analysis are performed rapidly</b> (it took about 1-3 minutes to automatically produce an AMR surveillance report using example data sets provided in the AMASS package).
	<b>No additional program or software is needed.</b> All the essential software is stored in the AMASS package and will operate automatically after a double click the application file (AMASS.bat).
	<b>Users do not need to understand R program or write any codes to run the AMASS application.</b>
<b>Highly-compatible</b>	<b>AMASS works with raw data files in either CSV or Excel format,</b> which can be commonly exported from WHONET and other software, program or data management systems used for microbiology data and hospital admission data.
	<b>AMASS uses data dictionary files (in Excel format) to accommodate data exported from different software, program or systems</b> that may have different ways to name data variables and data values (Figure 2).
	<b>AMASS dictionary files can be re-used by users in the future</b> (e.g. monthly, quarterly and yearly) if the structures of the new raw microbiology data file and hospital admission data file remain unchanged.
	<b>AMASS uses a tier-based approach based on availability of raw data files to generate reports.</b> Users with limited data availabilities (e.g. microbiology data with only culture positive results) can still utilize de-duplication and report generation functions of the AMASS. Users with additional data (e.g. microbiology data with culture negative results and hospital admission date data) will receive additional reports (e.g. sample-based surveillance report with stratification by infection origin).
<b>High data security</b>	<b>AMASS does not require the Internet to operate.</b> Users do not have to transfer raw individual data (which may contain identifiable information) to any institution outside

	of the hospital to analyse the data and generate the reports. AMASS can be run within a standalone computer within the local hospital under the local data security. Hence, the AMASS does not increase any risks of breaching individual patient data confidentiality.
<b>Easy-to-use outputs</b>	<b>The automatically generated AMR surveillance report is in PDF format</b> , which is easy to print, read and share within and outside the hospitals.
<b>Easy-to-share outputs</b>	<b>The report (in PDF format) and aggregated summary data files (in CSV format) contains no individual level patient data</b> , and could be readily shared with national and international organizations.

576

577

578

579

580 **References**

- 581 1. Limmathurotsakul D, Dunachie S, Fukuda K, et al. Improving the estimation  
582 of the global burden of antimicrobial resistant infections. *Lancet Infect Dis* 2019;  
583 19(11): e392-e8.
- 584 2. World Health Organization (WHO). Global antimicrobial resistance  
585 surveillance system (GLASS) report: Early implementation 2017-2018. 2019.  
586 [https://apps.who.int/iris/bitstream/handle/10665/279656/9789241515061-](https://apps.who.int/iris/bitstream/handle/10665/279656/9789241515061-eng.pdf?ua=1)  
587 [eng.pdf?ua=1](https://apps.who.int/iris/bitstream/handle/10665/279656/9789241515061-eng.pdf?ua=1) (accessed Dec 1, 2019).
- 588 3. Public Health England (PHE). Annual epidemiological commentary: Gram-  
589 negative bacteraemia, MRSA bacteraemia, MSSA bacteraemia and *C. difficile*  
590 infections, up to and including financial year April 2018 to March 2019. 2019.  
591 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attach](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/815449/Annual_epidemiological_commentary_April_2017_to_March_2019.pdf)  
592 [ment\\_data/file/815449/Annual\\_epidemiological\\_commentary\\_April\\_2017\\_to\\_March](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/815449/Annual_epidemiological_commentary_April_2017_to_March_2019.pdf)  
593 [2019.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/815449/Annual_epidemiological_commentary_April_2017_to_March_2019.pdf) (accessed Dec 1, 2019).
- 594 4. Johnson AP, Davies J, Guy R, et al. Mandatory surveillance of methicillin-  
595 resistant *Staphylococcus aureus* (MRSA) bacteraemia in England: the first 10 years.  
596 *J Antimicrob Chemother* 2012; 67(4): 802-9.
- 597 5. Amaratunga K, Tarasuk J, Tsegaye L, et al. Advancing surveillance of  
598 antimicrobial resistance: Summary of the 2015 CIDSC Report. *Can Commun Dis*  
599 *Rep* 2016; 42(11): 232-7.
- 600 6. The review on Antimicrobial Resistance. Tackling Drug-resistant Infections  
601 Globally: Final Report and Recommendation, 2016. [https://amr-](https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf)  
602 [review.org/sites/default/files/160518\\_Final%20paper\\_with%20cover.pdf](https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf) (accessed  
603 Dec 1, 2019).
- 604 7. Interagency Coordination Group on Antimicrobial Resistance. No time to wait:  
605 securing the future from drug-resistant infections, 2019.  
606 [https://www.who.int/antimicrobial-resistance/interagency-coordination-](https://www.who.int/antimicrobial-resistance/interagency-coordination-group/IACG_final_report_EN.pdf?ua=1)  
607 [group/IACG\\_final\\_report\\_EN.pdf?ua=1](https://www.who.int/antimicrobial-resistance/interagency-coordination-group/IACG_final_report_EN.pdf?ua=1) (accessed Dec 1, 2019).
- 608 8. World Economic Forum. The global risks report 2018- 13th Edition. 2018.  
609 [http://www3.weforum.org/docs/WEF\\_GRR18\\_Report.pdf](http://www3.weforum.org/docs/WEF_GRR18_Report.pdf) (accessed Dec 1, 2019).
- 610 9. Hall W, McDonnell A, O'Neill J. Superbugs: An Arms Race against Bacteria.  
611 Harvard University Press; 2018. Cambridge, Massachusetts; London, England:  
612 Harvard University Press, 2018.
- 613 10 de Kraker ME, Stewardson AJ, Harbarth S. Will 10 Million People Die a Year  
614 due to Antimicrobial Resistance by 2050? *PLoS Med* 2016; 13(11): e1002184.
- 615 11. World Health Organization (WHO). The Global Antimicrobial Resistance  
616 Surveillance System (GLASS)- Manual for early implementation. 2015.

- 617 [https://apps.who.int/iris/bitstream/handle/10665/188783/9789241549400\\_eng.pdf?se](https://apps.who.int/iris/bitstream/handle/10665/188783/9789241549400_eng.pdf?sequence=1)  
618 [quence=1](https://apps.who.int/iris/bitstream/handle/10665/188783/9789241549400_eng.pdf?sequence=1) (accessed Dec 1, 2019).
- 619 12. Clinical and Laboratory Standards Institute. Analysis and Presentation of  
620 Cumulative Antimicrobial Susceptibility Test Data, 4th Edition. 2014.
- 621 13. Public Health England (PHE). Biannual commentary on MRSA, MSSA and  
622 Gram-negative baceteraemia and Clostridium difficile infections from independent  
623 sector healthcare organisations in England; April 2017 to March 2018, 2018.
- 624 14. European Antimicrobial Resistance Surveillance Network. Antimicrobial  
625 resistance (AMR) reporting protocol 2018, 2018.  
626 [https://www.ecdc.europa.eu/sites/portal/files/documents/EARS-](https://www.ecdc.europa.eu/sites/portal/files/documents/EARS-Net%20reporting%20protocol%202018.%20docx.pdf)  
627 [Net%20reporting%20protocol%202018.%20docx.pdf](https://www.ecdc.europa.eu/sites/portal/files/documents/EARS-Net%20reporting%20protocol%202018.%20docx.pdf) (accessed Dec 1, 2019).
- 628 15. Centers for Disease Control and Prevention. Antibiotic resistance threats in  
629 the United States, 2019: U.S. Department of Health and Human Services Centers for  
630 Disease Control and Prevention, 2019.
- 631 16. World Health Organization (WHO). Antimicrobial resistance- Global report on  
632 surveillance, 2014.  
633 [https://apps.who.int/iris/bitstream/handle/10665/112642/9789241564748\\_eng.pdf;js](https://apps.who.int/iris/bitstream/handle/10665/112642/9789241564748_eng.pdf;jsessionid=18CA836B4A59D8644F0976415FC00F67?sequence=1)  
634 [essionid=18CA836B4A59D8644F0976415FC00F67?sequence=1](https://apps.who.int/iris/bitstream/handle/10665/112642/9789241564748_eng.pdf;jsessionid=18CA836B4A59D8644F0976415FC00F67?sequence=1) (accessed Dec 1,  
635 2019).
- 636 17. World Health Organization (WHO). Global Antimicrobial Resistance  
637 Surveillance System (GLASS) Report: Early implementation 2017-2018, 2018.  
638 [https://apps.who.int/iris/bitstream/handle/10665/279656/9789241515061-](https://apps.who.int/iris/bitstream/handle/10665/279656/9789241515061-eng.pdf?ua=1)  
639 [eng.pdf?ua=1](https://apps.who.int/iris/bitstream/handle/10665/279656/9789241515061-eng.pdf?ua=1) (accessed Dec 1, 2019).
- 640 18. Ashley EA, Shetty N, Patel J, et al. Harnessing alternative sources of  
641 antimicrobial resistance data to support surveillance in low-resource settings. The J  
642 Antimicrob Chemother 2019; 74(3): 541-6.
- 643 19. Kyobe S, Musinguzi H, Lwanga N, et al. Selecting a Laboratory Information  
644 Management System for Biorepositories in Low- and Middle-Income Countries: The  
645 H3Africa Experience and Lessons Learned. Biopreserv Biobank 2017; 15(2): 111-5.
- 646 20. Stelling JM, O'Brien TF. Surveillance of antimicrobial resistance: the  
647 WHONET program. Clin Infect Dis 1997; 24: S157-68.
- 648 21. Lim C, Takahashi E, Hongsuwan M, et al. Epidemiology and burden of  
649 multidrug-resistant bacterial infection in a developing country. Elife 2016; 5.
- 650 22. Gupta K, Scholes D, Stamm WE. Increasing prevalence of antimicrobial  
651 resistance among uropathogens causing acute uncomplicated cystitis in women.  
652 JAMA 1999; 281(8): 736-8.

- 653 23. Apte M, Neidell M, Furuya EY, Caplan D, Glied S, Larson E. Using  
654 electronically available inpatient hospital data for research. *Clin Transl Sci* 2011;  
655 4(5): 338-45.
- 656 24. Wyllie DH, Crook DW, Peto TE. Mortality after *Staphylococcus aureus*  
657 bacteraemia in two hospitals in Oxfordshire, 1997-2003: cohort study. *BMJ* 2006;  
658 333(7562): 281.
- 659 25. World Health Organization (WHO). Global priority list of antibiotic-resistant  
660 bacteria to guide research, discovery, and development of new antibiotics, 2017.  
661 [https://www.who.int/medicines/publications/WHO-PPL-Short\\_Summary\\_25Feb-](https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1)  
662 [ET\\_NM\\_WHO.pdf?ua=1](https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1) (accessed Dec 1, 2019).
- 663 26. Office for National Statistics. Deaths involving MRSA: England and Wales:  
664 Office for National Statistics, 2014.  
665 [https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/d](https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/deathsinvolvingmrsaenglandandwales)  
666 [eaths/datasets/deathsinvolvingmrsaenglandandwales](https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/deathsinvolvingmrsaenglandandwales) (accessed Dec 1, 2019).
- 667 27. Office for National Statistics. Deaths involving *Clostridium difficile*, 2017.  
668 [https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/d](https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/deathsinvolvingclostridiumdifficilereferencetables)  
669 [eaths/datasets/deathsinvolvingclostridiumdifficilereferencetables](https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/deathsinvolvingclostridiumdifficilereferencetables) (accessed Dec 1,  
670 2019).
- 671 28. Angkor Hospital for Children, Siem Reap. Antimicrobial resistance  
672 surveillance report, Angkor Hospital for Children, Cambodia, 01 Jan 2016 to 31 Dec  
673 2016; 2020. <https://doi.org/10.6084/m9.figshare.12000225.v1> (accessed Apr 18,  
674 2020).
- 675 29. Mahosot Hospital, Vientiane. Antimicrobial resistance surveillance report,  
676 Mahosot Hospital, Lao PDR, 01 Jul 2019 to 30 Sep 2019; 2020.  
677 <https://doi.org/10.6084/m9.figshare.12000222.v1> (accessed Apr 18, 2020).
- 678 30. North Okkalapa General and Teaching Hospital, Yangon. Antimicrobial  
679 resistance surveillance report, North Okkalapa General and Teaching Hospital,  
680 Myanmar, 02 Jan 2019 to 27 Dec 2019; 2020.  
681 <https://doi.org/10.6084/m9.figshare.12000237.v1> (accessed Apr 18, 2020).
- 682 31. Patan Hospital, Kathmandu. Antimicrobial resistance surveillance report,  
683 Patan Hospital, Nepal, 01 Jan 2018 to 30 Dec 2018; 2020.  
684 <https://doi.org/10.6084/m9.figshare.12000231.v1> (accessed Apr 18, 2020).
- 685 32. Sunpasitthiprasong Hospital, Ubon Ratchathani. Antimicrobial resistance  
686 surveillance report, Sunpasitthiprasong Hospital, Thailand, 01 Jan 2015 to 31 Dec  
687 2015; 2020. <https://doi.org/10.6084/m9.figshare.12000240.v1> (accessed Apr 18,  
688 2020).

- 689 33. St Thomas' Hospital, London. Antimicrobial resistance surveillance report, St  
690 Thomas' Hospital, United Kingdom, 01 Jan 2018 to 31 Dec 2018; 2020.  
691 <https://doi.org/10.6084/m9.figshare.12000249.v1> (accessed Apr 18, 2020).
- 692 34. The Hospital for Tropical Diseases, Ho Chi Minh City. Antimicrobial  
693 resistance surveillance report, The Hospital for Tropical Diseases, Vietnam, 01 Jan  
694 2017 to 30 Dec 2017; 2020. <https://doi.org/10.6084/m9.figshare.12000252.v1>  
695 (accessed Apr 18, 2020).
- 696 35. Turner P, Ashley EA, Celhay OJ et al. ACORN (A Clinically-Oriented  
697 Antimicrobial Resistance Surveillance Network): a pilot protocol for case based  
698 antimicrobial resistance surveillance. Wellcome Open Res 2020; 5:13.
- 699 36. Chang K, Rattanavong S, Mayxay M, et al. Bacteremia caused by extended-  
700 spectrum beta-lactamase-producing Enterobacteriaceae in Vientiane, Lao PDR: a 5-  
701 year study. Am J Trop Med Hyg 2020 [Epub ahead of print].
- 702 37. Sriboonsong S, Boonchoo L. Automatic antimicrobial susceptibility testing  
703 system. 2007; Berlin, Heidelberg: Springer Berlin Heidelberg; 2007. p. 2501-4.
- 704 38. O'Brien TF, Clark A, Peters R, Stelling J. Why surveillance of antimicrobial  
705 resistance needs to be automated and comprehensive. J Glob Antimicrob Resist  
706 2019;17:8-15.
- 707 39. Turner P, Ashley EA. Standardising the reporting of microbiology and  
708 antimicrobial susceptibility data. Lancet Infect Dis 2019; 19(11): 1163-4.
- 709 40. van Panhuis WG, Paul P, Emerson C, et al. A systematic review of barriers to  
710 data sharing in public health. BMC Public Health 2014;14:1144.
- 711 41. Tenopir C, Allard S, Douglass K, et al. Data sharing by scientists: practices  
712 and perceptions. PLoS One 2011; 6(6): e21101.